INFORMED.
LIVE

Sun Pharma Advanced Research Company Ltd.

BSE: SPARC532872ISIN INE232I01014
  • Healthcare
  • Pharmaceuticals
  • BSE 1000

Share price

₹194.05+0.75 (+0.39%)
as of 18 Sep 2026
Sun Pharma Advanced Research Company Ltd. share price, 18 Sep 2025 to 18 Sep 2026: ₹143.85 to ₹194.05 (+34.9%). Low ₹111.95, high ₹277.40. Volume shown below the price.
52W high
₹289.00
52W low
₹108.20
Off 52W high
-32.85%
1M return
+0.47%
3M return
-18.36%
6M return
+67.79%
1Y return
+34.90%
20D avg volume
73,003
50 DMA
₹209.33
200 DMA
₹170.41

Key ratios Consolidated

Market cap
₹6,297 Cr
Current price
₹194.05
52W high / low
₹289.00 / ₹108.20
Face value
₹1.00
P/E
3.97
P/B
EPS (TTM)
₹48.82
Book value / share
ROE
ROCE
112.00%
Operating margin
Net margin
Debt / equity
0.42
Net debt
₹554.98 Cr
Interest cover
46.50
Dividend yield
Dividend / share (TTM)
Payout
Cash conversion cycle
-17.3 days

About

In plain English

Sun Pharma Advanced Research Company (SPARC) is a research arm of the Sun Pharma group that focuses on creating new drugs and advanced drug delivery methods. For example, their product PDP-716 is a drug candidate for which they've filed a New Drug Application (a formal request to regulators for approval to sell the drug). They also license their technologies to other companies, like the recent agreement with CMS Bridging DMCC, which they later terminated. Their customers are typically other pharmaceutical companies and healthcare providers who buy or license their innovations. The company makes money by licensing out its drug candidates and technologies, and potentially from future sales of approved drugs.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 8 Jul 2026.

Financials

MetricQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q4 FY24
Income statement
39.921,8538.457.869.6427.19
23.661.800.000.019.140.00
84.2594.0676.4483.6670.5987.86
7.665.167.216.105.135.70
0.000.000.000.000.000.00
29.6126.0231.1829.5131.3229.85
8.1311.648.787.526.194.54
2.202.402.572.562.682.95
36.6548.8426.7037.9725.2744.82
-20.671,761-67.99-75.79-51.81-60.67
0.000.00-12.360.000.000.00
-20.671,761-80.35-75.79-51.81-60.67
0.11-0.380.070.060.06-0.90
-20.781,761-80.42-75.85-51.87-59.77
-0.6454.27-2.48-2.34-1.60-1.84
Key metrics
-10.341,775-69.00-65.71-42.94-53.18
-25.90%95.80%-816.60%-836.00%-445.40%-195.60%
-52.10%95.00%-951.70%-965.00%-538.10%-219.80%
125.10%40.30%145.00%
314.10%6,715.80%
59.90%3,046.90%
MetricTTMFY26FY25FY24
Income statement
1,9091,87971.77
25.4710.951.79
338.41324.75416.34
26.1323.6023.12
0.000.000.00
116.32118.03153.58
36.0734.139.04
9.7310.2112.39
150.16138.78218.21
1,5971,565-342.78
-12.36-12.360.00
1,5841,553-342.78
-0.14-0.19-0.27
1,5841,553-342.51
48.8147.86-10.55
Key metrics
1,6301,597-321.35
85.36%85.00%-447.70%
82.97%82.70%-477.20%
112.00%862.20%
2,518.30%
553.50%
-262.60-370.63
-0.151.05
0.42-1.19
554.98256.23
-17.3-497.7
Balance sheet
2,171335.53
1,86226.19
1.161.96
8.2716.06
0.000.00
1,8465.65
85.1898.70
97.15113.92
754.09374.24
556.14258.19
556.14158.19
0.00100.00
1,339-216.95
Cash flow
-238.77-360.29
-23.50157.66
261.39199.25
23.8310.34
MetricQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q4 FY24
Income statement
39.921,8538.457.869.6427.19
23.661.800.000.019.020.00
84.5694.3276.6683.8470.6988.17
7.665.167.216.105.135.70
0.000.000.000.000.000.00
24.1621.0826.9026.1927.6824.83
8.1311.648.787.526.184.51
2.202.402.562.572.542.55
42.4154.0431.2141.4629.1650.58
-20.981,761-68.21-75.97-52.03-60.98
0.000.00-12.360.000.000.00
-20.981,761-80.57-75.97-52.03-60.98
0.000.000.000.000.000.00
-20.981,761-80.57-75.97-52.03-60.98
-0.6554.26-2.48-2.34-1.60-1.88
Key metrics
-10.651,775-69.23-65.88-43.31-53.92
-26.70%95.80%-819.30%-838.20%-449.30%-198.30%
-52.60%95.00%-953.50%-966.50%-539.70%-224.30%
125.60%39.40%127.10%
314.10%6,715.80%
59.70%2,987.30%
MetricTTMFY26FY25FY24
Income statement
1,9091,87971.77
25.4710.831.79
339.38325.51418.78
26.1323.6023.12
0.000.000.00
98.33101.85108.96
36.0734.128.91
9.7310.0710.83
169.12155.87266.96
1,5961,564-345.22
-12.36-12.360.00
1,5831,552-345.22
0.000.000.00
1,5831,552-345.22
48.7947.83-10.64
Key metrics
1,6291,596-325.48
85.31%84.90%-453.50%
82.91%82.60%-481.00%
112.40%756.80%
2,518.30%
549.60%
-262.72-372.75
-0.151.05
0.42-1.17
555.82257.00
-19.0-550.9
Balance sheet
2,168329.29
1,86125.27
0.321.19
8.2716.06
0.000.00
1,8465.50
85.1895.27
106.31124.39
756.82373.73
556.14258.19
556.14158.19
0.00100.00
1,334-220.62
Cash flow
-238.89-362.41
-23.51157.66
261.53200.88
23.8310.34

Compounded growth

Standalone

Sales CAGR 3Y
Sales CAGR 5Y
Sales CAGR 10Y
Profit CAGR 3Y
Profit CAGR 5Y
Profit CAGR 10Y
Sales YoY (TTM)
Profit YoY (TTM)

Consolidated

Sales CAGR 3Y
Sales CAGR 5Y
Sales CAGR 10Y
Profit CAGR 3Y
Profit CAGR 5Y
Profit CAGR 10Y
Sales YoY (TTM)
Profit YoY (TTM)

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding
65.69%
Quarter30 Jun 2026June 2026
Promoter %65.69%65.69%
HolderTypeHoldingPreviousChange
Shanghvi Finance Private LimitedPromoter Group42.28%42.28%0.00%
Dilip.S.ShanghviPromoter19.05%19.05%0.00%
Sun Pharmaceutical Industries Key Employees Benefit TrustPublic3.18%3.18%0.00%
Lakshdeep Investments & Finance (P) Ltd.Public1.86%1.86%0.00%
Aditya Medisales LimitedPromoter Group1.51%1.51%0.00%
Raksha Sudhir ValiaPromoter Group1.28%1.28%0.00%
Paresh Mohanlal ParekhPublic1.13%1.13%0.00%
Vijay Mohanlal ParekhPublic1.13%1.13%0.00%
Enam Securities Private LimitedPublic1.04%1.04%0.00%
Sudhir Vrundavandas ValiaPromoter Group0.57%0.57%0.00%
Unimed Investments LimitedPromoter Group0.39%0.39%0.00%
Vibha Dilip ShanghviPromoter Group0.33%0.33%0.00%
Vidhi Dilip ShanghviPromoter Group0.11%0.11%0.00%
Aalok Dilip ShanghviPromoter Group0.11%0.11%0.00%
Shanghvi Family & Friends Benefit TrustPromoter Group0.05%0.05%0.00%

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Board meetings

  • Board Meeting - Financial Results